Synthetic Biologics Inc (NYSEMKT:SYN) stated loss of 525,826 shares or 7.2% in the short interest. The short interest registered from 7,305,029 on May 31,2016 to 6,779,203 on June 15,2016. In terms of floated shares, the shorted positions stood at 10.5%. The stock has been averaging 647,740 shares daily in trading and would need 10 days to cover the shorts. The information was released by Financial Industry Regulatory Authority, Inc (FINRA) on June 24th after market close.
Synthetic Biologics Inc (NYSEMKT:SYN): The stock opened at $1.75 on Friday but the bulls could not build on the opening and the stock topped out at $1.80 for the day. The stock traded down to $1.65 during the day, due to lack of any buying support eventually closed down at $1.70 with a loss of -3.41% for the day. The stock had closed at $1.76 on the previous day. The total traded volume was 7,451,535 shares.
The company shares have dropped -39.07% from its 1 Year high price. On Jul 15, 2015, the shares registered one year high at $4.32 and the one year low was seen on Feb 11, 2016. The 50-Day Moving Average price is $2.03 and the 200 Day Moving Average price is recorded at $2.00.
Synthetic Biologics Inc (NYSEMKT:SYN) has tumbled 4.49% during the past week and has dropped 19.81% in the last 4 week period. The stocks are negative as compared to the S&P 500 for the past week with a loss of 2.91%. Synthetic Biologics Inc (NYSEMKT:SYN) has underperformed the index by 17.39% in the last 4 weeks. Investors should watch out for further signals and trade with caution.
Synthetic Biologics, Inc. is a clinical-stage biotechnology company. The Company is developing pathogen-specific therapies for serious infections and diseases, with a focus on protecting the microbiome. It is developing an oral biologic to protect the gut microbiome (gastrointestinal (GI) microflora) from intravenous (IV) antibiotics for the prevention of C. difficile infection, an oral statin treatment to reduce the impact of methane producing organisms on irritable bowel syndrome with constipation (IBS-C) and a monoclonal antibody combination for the treatment of Pertussis. In addition, the Company is developing a Phase II oral estriol drug for the treatment of relapsing-remitting multiple sclerosis (MS) and cognitive dysfunction in MS.